Comparison 3. Propafenone versus placebo or no treatment.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All‐cause mortality – main analysis	2	212	Risk Ratio (M‐H, Fixed, 95% CI)	0.19 [0.02, 1.68]
2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events	3	406	Risk Ratio (M‐H, Fixed, 95% CI)	1.28 [0.45, 3.62]
3 All‐cause mortality – sensitivity analysis: low risk of bias studies	1	102	Risk Ratio (M‐H, Fixed, 95% CI)	0.11 [0.00, 2.64]
4 Withdrawals due to adverse effects – main analysis	5	1098	Risk Ratio (M‐H, Fixed, 95% CI)	1.62 [1.07, 2.46]
5 Withdrawals due to adverse effects – sensitivity analysis: studies > 200 participants	1	523	Risk Ratio (M‐H, Fixed, 95% CI)	1.29 [0.79, 2.11]
6 Proarrhythmia – main analysis	3	381	Risk Ratio (M‐H, Fixed, 95% CI)	1.32 [0.39, 4.47]
7 Proarrhythmia – sensitivity analysis: low risk of bias studies	1	102	Risk Ratio (M‐H, Fixed, 95% CI)	0.49 [0.09, 2.75]
8 Atrial fibrillation recurrence – main analysis	5	1098	Risk Ratio (M‐H, Fixed, 95% CI)	0.67 [0.61, 0.74]
9 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies	1	102	Risk Ratio (M‐H, Fixed, 95% CI)	0.71 [0.50, 1.01]
10 Atrial fibrillation recurrence – sensitivity analysis: studies > 200 participants	1	523	Risk Ratio (M‐H, Fixed, 95% CI)	0.71 [0.63, 0.79]